Pemetrexed Pfizer (previously Pemetrexed Hospira)

A risk management plan has been developed to ensure that Pemetrexed Hospira is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed Hospira, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the Pemetrexed Hospira : EPAR - Risk-management-plan summary.

Because Pemetrexed Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The European Commission granted a marketing authorisation valid throughout the European Union for Pemetrexed Hospira on 20 November 2015.

For more information about treatment with Pemetrexed Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

The full EPAR for the reference medicine can also be found on the Agency’s website.

Pemetrexed Hospira is available as a powder that is made up into a solution for infusion (drip) into a vein. The medicine can only be obtained with a prescription and should only be given under the supervision of a doctor who is qualified in the use of chemotherapy.

The recommended dose is 500 mg per square metre of body surface area (calculated using the patient’s height and weight). It is given once every three weeks as an infusion lasting 10 minutes. To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Hospira. When Pemetrexed Hospira is given with cisplatin, an ‘anti-emetic’ medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.

Treatment should be delayed or stopped, or the dose reduced, in patients whose blood counts are abnormal or who have certain other side effects. For more information, see the summary of product characteristics (also part of the EPAR).

The active substance in Pemetrexed Hospira, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites’. In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells). As a result, the active form of pemetrexed slows down the formation of DNA and RNA and prevents the cells from dividing and multiplying. The conversion of pemetrexed into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells. This results in the division of cancer cells being reduced, while normal cells are only slightly affected.

The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed Hospira has been shown to be comparable to Alimta. Therefore, the CHMP’s view was that, as for Alimta, the benefit outweighs the identified risk. The Committee recommended that Pemetrexed Hospira be approved for use in the EU.

Pemetrexed Hospira is a cancer medicine used to treat two types of lung cancer:

• malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery;
• advanced non-small-cell lung cancer of the kind known as ‘non-squamous’, where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment. It can also be used as a maintenance treatment in patients who have received a platinum-based chemotherapy.

Pemetrexed Hospira is a ‘generic medicine’. This means that Pemetrexed Hospira is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Alimta.

Pemetrexed Hospira contains the active substance pemetrexed.

The company provided data from the published literature on pemetrexed. No additional studies were needed as Pemetrexed Hospira is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.

Pemetrexed Pfizer can only be obtained with a prescription and should only be given under the supervision of a doctor who is qualified in the use of chemotherapy. It is given as an infusion (drip) into a vein, once every three weeks. The recommended dose depends on the patient’s height and weight.

To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Pfizer. When Pemetrexed Pfizer is given with cisplatin, an ‘anti-emetic’ medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose. Treatment should be delayed or stopped, or the dose reduced, in patients whose blood counts are abnormal or who have certain other side effects.

For more information about using Pemetrexed Pfizer, see package leaflet or contact your doctor or pharmacist .

The active substance in Pemetrexed Pfizer, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites’. In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells). As a result, the active form of pemetrexed slows down the formation of DNA and RNA and prevents the cells from dividing and multiplying. The conversion of pemetrexed into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells. This results in the division of cancer cells being reduced, while normal cells are only slightly affected.

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Alimta, and do not need to be repeated for Pemetrexed Pfizer.

The company provided data from the published literature on pemetrexed. There was no need for ‘bioequivalence’ studies to investigate whether Pemetrexed Pfizer is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Pemetrexed Pfizer is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

Because Pemetrexed Pfizer is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The European Medicines Agency concluded that, in accordance with EU requirements, Pemetrexed Pfizer has been shown to be comparable to Alimta. Therefore, the Agency’s view was that, as for Alimta, the benefits of Pemetrexed Pfizer outweigh the identified risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pemetrexed Pfizer have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Alimta also apply to Pemetrexed Pfizer where appropriate.

As for all medicines, data on the use of Pemetrexed Pfizer are continuously monitored. Suspected side effects reported with Pemetrexed Pfizer are carefully evaluated and any necessary action taken to protect patients.

Pemetrexed Hospira received a marketing authorisation valid throughout the EU on 20 November 2015.

The name of the medicine was changed to Pemetrexed Pfizer on 29 August 2022.